We are live on ! Find out more
MESO icon

Mesoblast

43 hedge funds and large institutions have $12.4M invested in Mesoblast in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

430% more call options, than puts

Call options by funds: $6.75M | Put options by funds: $1.27M

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

27% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 11

25% more capital inflows, than outflows

Capital inflows: $2.13M | Capital outflows: $1.71M

10% more funds holding

Funds holding: 39 → 43 (+4)

0.05% more ownership

Funds ownership: 1.3% → 1.35% (+0.05%)

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
14
Reduced
11
Closed
4
Calls
$6.75M
Puts
$1.27M
Net Calls
+$5.48M
Net Calls Change
+$4.59M

MESO Hedge Fund Activity: Q3 2024 in Review

43 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Mesoblast (MESO) for Q3 2024, worth a combined $12.4M — up 23% from $10.1M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MESO positions and 4 closed out — a net gain of 5 holders — while 14 added to existing stakes and 11 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $611K. The largest seller was Marshall Wace, cutting an estimated $440K.

  • 43 institutional investors held Mesoblast (MESO) as of Q3 2024, up from 39 in Q2 2024.
  • Funds reported $12.4M of Mesoblast stock for Q3 2024, up 23% quarter-over-quarter.
  • 9 funds opened new Mesoblast positions in Q3 2024 and 4 closed out, a net change of +5 holders.
  • The largest Mesoblast buyer in Q3 2024 was Morgan Stanley, an estimated $611K added.
  • The largest Mesoblast seller in Q3 2024 was Marshall Wace, an estimated $440K sold.

Based on aggregated 13F filings for Q3 2024.